Core Insights - Kairos Pharma Ltd. has been awarded the 2025 Clinical Trials Arena Excellence Award for its Research and Development efforts in Advanced Prostate Cancer [1] - The award recognizes the company's innovative approach in developing ENV105 (carotuximab), a first-in-class monoclonal antibody targeting CD105 to combat treatment resistance in metastatic castration-resistant prostate cancer (mCRPC) [2][4] Company Overview - Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company based in Los Angeles, focusing on oncology therapeutics and utilizing structural biology to address drug resistance and immune suppression in cancer [5] - The lead candidate, ENV-105, targets CD105, a protein linked to resistance in various cancer treatments, aiming to restore the effectiveness of standard therapies [5] Clinical Trial Results - Positive interim results from a Phase 2 randomized clinical trial of ENV-105 in combination with apalutamide showed clinical benefit in 86% of treated patients, with all responders remaining progression-free for at least four months and half for over one year [3] - ENV-105 is currently in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs [5] Industry Recognition - The Clinical Trials Arena Excellence Awards highlight advancements in clinical research and drug development that can improve patient outcomes and redefine standards of care in the life sciences industry [4]